Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
it is not yet MHRA-licensed in the UK
cardiovascular, renal, and liver-disease trials read out through 2026 and 2027
Pharma giant Eli Lilly also is pushing to get FDA approval for tirzepatide, a diabetes medication, to be added to the weight loss market in the U.S
Gallbladder disease: Rapid weight loss is associated with an increased risk of gallstones and gallbladder inflammation (cholecystitis)
Availability depends on regulatory review, approximately 10 to 12 months for FDA review, and production scale-up post-approval
Nausea, diarrhea, and vomiting were the most common complaints, occurring primarily during dose escalation periods
US$ 29.64
US$ 25.09
US$ 22.33
